Renalytix PLC Change of public accounting firm
25 June 2024 - 4:00PM
RNS Regulatory News
RNS Number : 6900T
Renalytix PLC
25 June 2024
Renalytix
plc
("Renalytix" or the "Company")
Change of
public accounting firm
LONDON and NEW YORK, 25 June
2024 - Renalytix
plc (NASDAQ: RNLX) (LSE:
RENX) announces the appointment of
CohnReznick LLP as the Company's US independent
registered public accounting firm for the fiscal year ended June
30, 2024.
On June 21, 2024, Ernst & Young
LLP, was informed of their dismissal as the Company's independent
registered public accounting firm with such dismissal to be
effective as of June 18, 2024.
James McCullough, CEO of Renalytix plc,
commented: "We will continue to look
for opportunities to improve cost efficiencies and grow revenue as
they become available. We are reducing administrative expenses to
allocate more resources into sales and marketing, which is proving
effective."
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
Paul McManus / Alice Woodings
/
Charlotte Edgar
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
Mob: 07980
541 893 / 07407 804 654 /
07884 664
686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or
investors@renalytix.com
|
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an artificial intelligence enabled in-vitro diagnostics and laboratory
services company that is the global founder and leader in the field
of bioprognosis™ for kidney health. In late 2023, our
kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages
1-3b) risk assessment for progressive decline in kidney function in
T2D patients. By understanding how disease will progress, patients
and clinicians can take action earlier to improve outcomes and
reduce overall health system costs. For more information,
visit
www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPXZLLLZQLLBBX
Renalytix (LSE:RENX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Jul 2023 to Jul 2024